**Supplementary Table S4.** Summary of subgroup analysis results

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Intervention** | **Comparator** | **Incremental LY** | **Incremental QALY** | **Incremental costs** | **ICER (Cost/QALY)** |
| Pembrolizumab plus taxane | Taxane | 1.656 | 1.382 | $169,608 | $122,768 |
| Pembrolizumab plus gemcitabine plus carboplatin | Gemcitabine plus carboplatin | 0.260 | 0.216 | $110,305 | $511,640 |
| Pembrolizumab plus nab-paclitaxel | Nab-paclitaxel | 1.671 | 1.401 | $172,081 | $122,866 |
| Pembrolizumab plus paclitaxel | Paclitaxel | 2.028 | 1.676 | $188,388 | $112,399 |

**Abbreviations:** ICER: incremental cost-effectiveness ratio; LY: life years; QALY: quality-adjusted life years.